Curosurf 80mg Injection

Introduction

Curosurf is a prescription medication that contains the active ingredient Poractant Alfa. It is available under the brand name Curosurf. This medication is primarily used in the treatment of respiratory distress syndrome (RDS) in premature infants.

Uses

Curosurf is prescribed to help treat respiratory distress syndrome (RDS) in premature infants. RDS is a condition that affects the lungs of premature babies, causing difficulty in breathing due to underdeveloped lungs and insufficient surfactant production. This medication helps to improve lung function and reduce respiratory distress in these infants.

Dosage and Administration

Curosurf is administered by healthcare professionals in a hospital setting. The dosage and administration of this medication are determined by the infant’s weight and clinical condition. The healthcare provider will calculate the appropriate dose and administer it directly into the baby’s lungs using a special catheter. The injection is typically given shortly after birth and may be repeated if necessary.

Mechanism of Action

Poractant Alfa, the active ingredient in Curosurf, is a synthetic surfactant. Surfactant is a substance naturally produced by the lungs that helps reduce surface tension and allows the lungs to expand and contract easily during breathing. In infants with respiratory distress syndrome, there is a deficiency of surfactant, leading to breathing difficulties. Poractant Alfa replenishes the surfactant levels in the lungs, making it easier for the baby to breathe and improving overall lung function.

Side Effects

Common side effects may include transient bradycardia (temporary slowing of the heart rate), oxygen desaturation (lower levels of oxygen in the blood), and endotracheal tube reflux (backflow of stomach contents into the windpipe). These side effects are usually temporary and resolve on their own.

Serious side effects are rare but may include infection, bleeding, or pneumothorax (collection of air in the chest causing lung collapse). If any of these serious side effects occur, seek immediate medical attention.

Drug Interactions

There are currently no known drug interactions with Curosurf. However, it is always important to inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal supplements, that you are taking before starting this medication.

Precautions

Before using Curosurf, inform your healthcare provider about any known allergies to Poractant Alfa or any other surfactant medications. Additionally, let your healthcare provider know about any other medical conditions you have, especially if your baby has a history of bleeding disorders or lung infections. This medication should only be used under the supervision of a healthcare professional experienced in neonatal care.

Storage

Patient Tips

• Curosurf is administered by healthcare professionals in a hospital setting. Follow the instructions and recommendations provided by your healthcare team.
• During the administration of the injection, it is normal for your baby to be closely monitored for any potential side effects or reactions.
• If you have any concerns or questions about the medication or your baby’s condition, do not hesitate to reach out to your healthcare provider.
• Be sure to keep all follow-up appointments with your healthcare provider to monitor your baby’s progress and adjust the treatment plan if necessary.
• Store the medication as directed and keep it out of reach of children.
• Do not use the medication if it appears cloudy, discolored, or contains particles.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Curosurf 120mg / vial Endotracheopulmonary Instillation Suspension (Health Professionals SmPC) Available at:
• Poractant Alfa (Drugs.com) [Accessed 28 Jun. 2024] (online) Available at:
• Lemyre B, Lacaze-Masmonteil T, Shah PS, Bodani J, Doucette S, Dunn M, Louis D, Monterrosa L, Mukerji A, Schmölzer GM, Singh B, Wong J, Ye XY, Offringa M. Poractant alfa versus bovine lipid extract surfactant: prospective comparative effectiveness study. J Perinatol. 2022 Apr;42(4):468-475. doi: 10.1038/s41372-022-01346-0. Epub 2022 Feb 18. [Accessed 30 Jun. 2024] Available at:
• Lemyre B, Fusch C, Schmölzer GM, Rouvinez Bouali N, Reddy D, Barrowman N, Huneault-Purney N, Lacaze-Masmonteil T. Poractant alfa versus bovine lipid extract surfactant for infants 24+0 to 31+6 weeks gestational age: A randomized controlled trial. PLoS One. 2017 May 4;12(5):e0175922. doi: 10.1371/journal.pone.0175922. eCollection 2017. [Accessed 11 Jun. 2024] Available at: